1. A 58-year-old man with a 40 pack-year smoking history presents with right-sided ptosis, right pupil measuring 2 mm (left pupil 5 mm) with preserved light reflex, and absence of sweating over the right face. He reports three months of progressive right shoulder pain. Chest CT reveals a 3.8 cm spiculated right apical mass with first and second rib involvement. Which of the following most accurately identifies the anatomical mechanism producing his ocular and facial findings, and predicts what pharmacological testing would confirm the diagnosis?

• A) The apical mass is compressing the right vagus nerve (CN X) as it descends into the thorax, disrupting parasympathetic tone to the right eye; topical pilocarpine 0.1% instilled in both eyes would produce greater miosis in the right eye than the left due to M3 receptor supersensitivity from parasympathetic denervation -- confirming vagal compression as the mechanism.
• B) The apical mass is compressing the right brachial plexus at C8-T1, producing lower trunk plexopathy with associated autonomic fiber involvement; topical cocaine 4% would dilate both pupils equally because the sympathetic deficit is preganglionic and NE stores at the postganglionic terminal are intact.
• C) The apical mass is disrupting the right second-order sympathetic neuron as it travels from the T1-T2 IML over the right pulmonary apex through the stellate ganglion en route to the superior cervical ganglion -- producing Horner syndrome (ptosis from superior tarsal muscle denervation, miosis from dilator pupillae denervation, and hemifacial anhidrosis from loss of sympathetic sudomotor fibers) by interrupting the second-order neuron before it reaches the superior cervical ganglion; topical cocaine 4-10% would fail to dilate the right pupil confirming sympathetic pathway interruption, while hydroxyamphetamine 1% would dilate the right pupil confirming the third-order neuron and its NE stores are intact, localizing the lesion to the first or second order neuron.
• D) The apical mass is compressing the right phrenic nerve, producing diaphragmatic hemiparesis on the right; the ptosis and miosis are incidental findings from a separate cranial nerve lesion unrelated to the lung mass; the anhidrosis reflects decreased respiratory effort reducing overall sympathetic tone bilaterally through central respiratory-autonomic coupling mechanisms.
• E) The apical mass has invaded the right superior cervical ganglion directly, producing third-order Horner syndrome; topical cocaine 4% would dilate both pupils equally because cocaine's mechanism requires intact sympathetic tone, which is preserved in third-order lesions since the first and second order neurons are intact and maintaining baseline NE release at the postganglionic terminal despite the ganglion's structural disruption.

2. A 74-year-old woman with COPD (FEV1 52% predicted) and heart failure with reduced ejection fraction (EF 30%) is started on carvedilol 3.125 mg twice daily at hospital discharge. Her COPD is managed with tiotropium inhaler daily. Three days after discharge she calls reporting worsening shortness of breath, audible wheeze, and her home peak flow has dropped from baseline 280 L/min to 160 L/min. Which of the following most accurately explains the receptor pharmacology producing this deterioration and identifies the preferred management?

• A) Carvedilol's alpha-1 blocking activity has blocked adrenergic vasodilation of the bronchial vasculature, producing mucosal congestion and mechanical airway narrowing that mimics bronchospasm; nebulized phenylephrine (alpha-1 agonist) would restore bronchial vasoconstriction and relieve the airway edema without worsening the underlying beta-2 bronchospasm caused by carvedilol's additional non-selective beta-blockade.
• B) Carvedilol is a non-selective beta-adrenergic blocker (blocking both beta-1 and beta-2 receptors) with additional alpha-1 blocking activity -- its beta-2 blockade removes the sympathetic bronchodilatory counterbalance to resting vagal M3-mediated bronchomotor tone, precipitating clinically significant bronchoconstriction in this patient with COPD and pre-existing bronchial hyperresponsiveness; management requires stopping carvedilol and substituting a highly cardioselective beta-1 blocker (bisoprolol or metoprolol succinate) with careful pulmonary monitoring; cardioselective beta-1 blockers are not absolutely contraindicated in COPD and carry clear mortality benefit in HFrEF; acute bronchospasm should be treated with inhaled SABA (salbutamol) to reverse the M3-mediated bronchoconstriction that beta-2 blockade has unmasked.
• C) Carvedilol's alpha-1 blocking activity has blocked alpha-1 receptors on bronchial smooth muscle, producing paradoxical bronchoconstriction through an alpha-1 receptor-mediated Gq/IP3/calcium signaling cascade; the drop in peak flow reflects this direct bronchoconstrictive mechanism rather than any beta-2 receptor involvement; the treatment is to maintain carvedilol but add inhaled ipratropium to block the alpha-1-mediated bronchoconstriction at the muscarinic level.
• D) The deterioration reflects decompensation of her underlying heart failure caused by the negative inotropic effect of carvedilol in a patient with severely reduced EF -- the wheeze is cardiac asthma from pulmonary venous congestion secondary to reduced cardiac output; IV furosemide is the correct initial management rather than any manipulation of the beta-blocker.
• E) Carvedilol selectively inhibits beta-2 receptors in the bronchial wall through a concentration-dependent mechanism independent of its beta-1 blocking activity -- at the low starting dose of 3.125 mg twice daily, carvedilol paradoxically exhibits greater beta-2 selectivity than beta-1 selectivity in bronchial tissue, and this effect reverses at higher doses; reducing the carvedilol dose rather than stopping it would restore the appropriate beta-1 to beta-2 blocking ratio and relieve the bronchoconstriction.

3. A 45-year-old man with severe refractory hypertension (BP 228/148 mmHg) complicated by acute aortic dissection is admitted to the ICU. The team considers trimethaphan IV for rapid blood pressure control while preparing for definitive surgical management. Which of the following most accurately predicts the complete autonomic profile of trimethaphan blockade and explains why ganglionic blockers have been largely abandoned in favor of more targeted antihypertensives?

• A) Trimethaphan selectively blocks sympathetic ganglia in the paravertebral chain while sparing parasympathetic ganglia in the cranial nerve ganglia and pelvic plexus -- the resulting selective sympatholysis produces hypotension and reflex tachycardia (from unopposed vagal tone) without any parasympatholytic effects, making it pharmacologically equivalent to a high-dose peripheral alpha-1 blocker plus centrally acting agent combination.
• B) Trimethaphan produces profound bradycardia from unopposed parasympathetic vagal tone that is released when sympathetic ganglionic transmission is blocked -- because the sympathetic division normally suppresses vagal tone through central sympathetic-parasympathetic reciprocal inhibition, sympathetic blockade removes this central suppression and reveals massive vagal predominance at the SA node; the resulting bradycardia requires atropine administration to maintain adequate cardiac output.
• C) Trimethaphan selectively blocks nicotinic NN receptors at autonomic ganglia while additionally blocking nicotinic NM receptors at the neuromuscular junction at higher doses, producing partial neuromuscular blockade that requires dose-dependent vecuronium supplementation to achieve complete surgical relaxation; this dual ganglionic-plus-NMJ blockade profile is the principal reason aortic dissection surgeons prefer trimethaphan over sodium nitroprusside for intraoperative blood pressure control.
• D) Trimethaphan acts exclusively on muscarinic M2 receptors at the sinoatrial node and muscarinic M3 receptors at vascular smooth muscle -- it is therefore pharmacologically identical to atropine in its cardiac effects but distinguishable from atropine by its additional direct vasodilatory action at M3 receptors; the combination of SA node M2 blockade and vascular M3 blockade produces the hypotension and tachycardia characteristic of ganglionic blockade.
• E) Trimethaphan produces hypotension (loss of sympathetic alpha-1-mediated vascular tone), tachycardia (from loss of dominant resting vagal M2-mediated SA node inhibition -- vagal tone is removed simultaneously with sympathetic tone), mydriasis, cycloplegia, dry mouth, urinary retention, constipation, and anhidrosis -- all reflecting simultaneous blockade of both sympathetic and parasympathetic ganglionic NN receptors; this non-selective profile combined with rapid tachyphylaxis and the availability of more targeted vasodilators (sodium nitroprusside, esmolol, nicardipine) explains why ganglionic blockers are now rarely used.

4. A 32-year-old woman at 34 weeks gestation develops urinary retention after an uncomplicated vaginal delivery with epidural analgesia, with a post-void residual of 520 mL confirmed on bladder ultrasound. Her obstetrician considers bethanechol 25 mg orally. Which of the following correctly identifies the anatomical basis for postpartum urinary retention in this setting, the mechanism by which bethanechol addresses it, and an important contraindication that must be excluded before prescribing?

• A) Postpartum urinary retention occurs because epidural analgesia blocks sacral parasympathetic outflow (S2-S4), eliminating M3-mediated detrusor contraction that is required for voiding; bethanechol, a direct-acting muscarinic agonist with preferential M3 activity that is resistant to acetylcholinesterase hydrolysis, bypasses the blocked neural pathway and directly stimulates detrusor M3 receptors producing coordinated contraction; before prescribing, bladder outlet obstruction must be excluded (bethanechol forcefully contracts the detrusor against a mechanical obstruction, risking bladder rupture) and asthma must be noted as a relative contraindication (systemic muscarinic agonism may produce bronchospasm).
• B) Postpartum urinary retention occurs because sympathetic alpha-1 receptors on the internal urethral sphincter are overactivated after delivery by catecholamine surge from labor pain, producing internal sphincter hypertonicity that prevents voiding despite normal detrusor function; bethanechol corrects this by activating alpha-2 receptors on the internal sphincter smooth muscle, inhibiting the alpha-1-mediated contraction through presynaptic suppression of norepinephrine release from the sympathetic nerve terminals that are maintaining sphincter tone.
• C) Postpartum urinary retention occurs because the fetal head compresses the pudendal nerve during descent through the birth canal, producing somatic motor denervation of the external urethral sphincter and paradoxical sphincter spasm -- bethanechol corrects this by activating nicotinic NM receptors at the external sphincter neuromuscular junction, overriding the damaged pudendal motor input with a pharmacological depolarizing stimulus that relaxes the spastic external sphincter.
• D) Bethanechol activates beta-3 adrenergic receptors on the detrusor muscle, producing the relaxation needed during the filling phase to increase bladder capacity and relieve urgency causing reflex sphincter spasm -- beta-3 agonism during the filling phase paradoxically promotes voiding by eliminating the urgency that was reflexly inhibiting micturition through pontine micturition center inhibitory pathways.
• E) Postpartum urinary retention occurs because prostaglandin F2-alpha released during labor activates FP receptors on detrusor smooth muscle, producing paradoxical detrusor relaxation rather than contraction; bethanechol corrects this by competitively blocking FP receptors at the detrusor while simultaneously activating muscarinic M3 receptors on the bladder neck to reduce outflow resistance -- a dual mechanism that requires higher bethanechol doses in the immediate postpartum period than at other times.